BEAM

Beam Therapeutics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Beam Therapeutics sales and earnings growth
BEAM Growth
Low
  • Revenue Y/Y↓ -84.07%
  • EPS Y/Y↓ -180.38%
  • FCF Y/Y↓ -142.38%
Beam Therapeutics gross and profit margin trends
BEAM Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -744.40%
  • ROIC↓ -43.30%
Beam Therapeutics net debt vs free cash flow
BEAM Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Beam Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗